4 unknown, 3 terminated, 2 completed, 1 not yet recruiting. 10 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Unknown 4, Terminated 3, Completed 2, Not yet recruiting 1 |
| Phase 1 | 1 | Unknown 1 |
Follow Muscle Invasive Bladder Cancer: new trials by email Literature Review of Muscle Invasive Bladder Cancer trials Research Report on Muscle Invasive Bladder Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sasanlimab As Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized Muscle Invasive Bladder Cancer Patients gemcitabine + cisplatine - Mibc, Muscle Invasive Bladder Cancer | Phase 2 | Not yet recruiting | Fundación de investigación HM | 70 | 2024-12-01 | 2024-10-04 |
| RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC Disitamab Vedotin and Toripalimab - Muscle Invasive Bladder Cancer, HER2 Expression | Phase 2 | Unknown | RenJi Hospital | 6 | 2023-08-01 | 2023-08-31 |
| A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer APL-1202 in combination with tislelizumab, Tislelizumab alone - Muscle Invasive Bladder Cancer | Phase 1 / Phase 2 | Unknown | Jiangsu Yahong Meditech Co., Ltd aka Asieris | 79 | 2021-12-28 | 2022-02-22 |
| Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma Tislelizumab, Nab paclitaxel - Muscle Invasive Bladder Cancer, Urothelial Carcinoma | Phase 2 | Unknown | Tianjin Medical University Second Hospital | 48 | 2020-07-11 | 2022-11-30 |
| Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer pegylated liposomal doxorubicin (PLD), PD-1 - Muscle Invasive Bladder Cancer | Phase 2 | Unknown | Tianjin Medical University Second Hospital | 60 | 2019-09-17 | 2019-09-26 |
| Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma dose dense MVAC with pegylated GCSF - Muscle Invasive Bladder Cancer, Urothelial Carcinoma | Phase 2 | Terminated | Pusan National University Yangsan Hospital | 24 | 2019-05-01 | 2026-09-18 |
| Avelumab and Radiation in Muscle-Invasive Bladder Cancer Avelumab, Radiation - Bladder Cancer, Muscle Invasive Bladder Cancer | Phase 2 | Terminated | Dana-Farber Cancer Institute | 14 | 2018-12-13 | 2025-10-31 |
| Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Rucaparib - Bladder Cancer, Urothelial Carcinoma | Phase 2 | Terminated | pharmaand GmbH | 97 | 2018-06-01 | 2023-06-09 |
| BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy Nivolumab, Cisplatin, Gemcitabine - Muscle Invasive Bladder Cancer | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 43 | 2018-01-29 | 2021-12-16 |
| Dose Dense MVAC for Muscle Invasive Bladder Cancer single arm dose dense MVAC - Muscle Invasive Bladder Cancer, High Risk Urothelial Carcinoma of the Upper Urinary Tracts | Phase 2 | Completed | Fox Chase Cancer Center | 54 | 2009-12-07 | 2019-09-17 |
Carcinoma, Transitional Cell (3) · Urinary Bladder Neoplasms (3) · Neoplasms (1) · Ureteral Neoplasms (1) · Urethral Neoplasms (1)
Neoplasms (5) · Carcinoma (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Male Urogenital Diseases (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Glandular and Epithelial (3) · Urinary Bladder Diseases (3) · Urogenital Diseases (3) · Urogenital Neoplasms (3) · Urologic Diseases (3) · Urologic Neoplasms (3) · Ureteral Diseases (1) · Urethral Diseases (1)
Cisplatin (2) · Gemcitabine (2) · tislelizumab (2) · Doxorubicin (1) · Methotrexate (1) · Nivolumab (1) · Platinum (1) · RC48 antibody (1) · Radiation (1) · Sodium (1) · Taxes (1) · Vinblastine (1) · avelumab (1) · disitamab vedotin (1) · liposomal doxorubicin (1)
Tianjin Medical University Second Hospital (2) · Dana-Farber Cancer Institute (1) · Fox Chase Cancer Center (1) · Fundación de investigación HM (1) · Jiangsu Yahong Meditech Co., Ltd aka Asieris (1) · Masonic Cancer Center, University of Minnesota (1) · Pusan National University Yangsan Hospital (1) · RenJi Hospital (1) · pharmaand GmbH (1)
United States (5) · China (4) · Spain (2) · France (1) · Germany (1) · Italy (1) · South Korea (1) · United Kingdom (1)
Badrinath Konety, MD, MBA (1) · Elizabeth Plimack, MD (1) · Haige Chen (1) · Hailong Hu, MD,PhD (1) · Kent Mouw, MD, PhD (1) · Kwonoh Park, MD, PhD (1) · Shilpa Gupta, MD (1)
PMID 24821881, PMID 11352955, PMID 11600601, PMID 12586807, PMID 12771730, PMID 12944571, PMID 15939524, PMID 16034041, PMID 21502557, PMID 24373477, PMID 24472710, PMID 24669010, PMID 24821883, PMID 25257030, PMID 26205531, PMID 26421586, PMID 27053504, PMID 28625005, PMID 29329894, PMID 34030643, PMID 37880682, PMID 37965307, PMID 40774226, PMID 42639047
2017 (1)